2022 Revenues ($USD) : $9,479,000,000
2022 R&D spend : n/a
2022 Number of Employees : 30,000
Fiscal Year End : 9/30/2021
Company CEO : Tom Polen, chair, CEO and president.

Franklin Lakes, New Jersey-based Becton, Dickinson (BD) was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. The medtech company has medical, life sciences and interventional business segments. As of the end of BD’s previous full fiscal year (September 2021), the company employed approximately 75,000 associates across 62 countries. That number will have shifted by now as the company successfully spun off its diabetes business, which is now a publicly traded company called Embecta.

The company’s medical segment, which previously included the diabetes business, underwent a number of changes at the top in 2022. First, there was the appointment of Simon Campion as EVP and president of the medical segment. BD announced in March that Alberto Mas intended to retire from the role. Campion’s position was made effective on July 1, 2022, but he spent less than two months running the segment, departing in late August for the corner office at Dentsply Sirona. Mike Garrison, who has been the worldwide president of BD Medication Management Solutions since 2020, will now be the new medical segment president.

In July, BD added to its offerings when it acquired Parata Systems for more than $1.5 billion. Parata provides medication adherence packaging technology and perpetual inventory management, with its automation technology and software designed to enable pharmacists to focus more on clinical work and patient interactions. The company is also currently facing a shareholder lawsuit over its much-maligned Alaris infusion pump system. The lawsuit involves how the company communicated its performance amid increasingly serious issues with the platform. –SW

*The 2022 Big 100 report is moving to September versus November in previous years. Because its fiscal year ends in September, BD's revenue number is the same as in the 2021 report.